DS
SAGE

DRW Securities’s Sage Therapeutics SAGE Stock Holding History

DRW Securities’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-10,300
Closed -$330K – 91
2016
Q1 		$330K Buy
10,300
+3,300
+47% +$116K 0.02% 60
2015
Q4 		$408K Buy
+7,000
New +$347K 0.04% 52

Other funds holding SAGE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

DRW Securities's SAGE Position: Q2 2016 in Review

DRW Securities sold out of Sage Therapeutics (SAGE) in Q2 2016, closing a stake of 10,300 shares — an estimated $330K sold.

DRW Securities first reported a position in SAGE in Q4 2015 and held it in 2 quarters. The position peaked at $408K in Q4 2015. 145 funds tracked by Wall St. Rank hold SAGE as of Q2 2016.

  • DRW Securities reported no remaining Sage Therapeutics position as of Q2 2016 after selling out during the quarter.
  • DRW Securities sold 10,300 Sage Therapeutics shares in Q2 2016, an estimated $330K.
  • DRW Securities first reported a position in Sage Therapeutics in Q4 2015 and held it in 2 quarters.
  • DRW Securities's Sage Therapeutics position peaked at $408K in Q4 2015.
  • 145 funds tracked by Wall St. Rank held Sage Therapeutics as of Q2 2016.

Based on DRW Securities's 13F filing for Q2 2016, filed 15 Aug 2016.